The role of the endocannabinoid system in the pathophysiology of mood disorders;Il ruolo del sistema endocannabinoide nella fisiopatologia dei disturbi dell'umore

Italian Journal of Psychopathology

Volumn 17, Issue 1, 2011, Pages 78-91

  Serra, G ^c   Bogliolo, V ^a   Garzia, A ^a   Zazzara, F ^b   Koukopoulos, A ^b   Demontis, F ^a   Serra, Gino ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b Centro Lucio Bini   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cannabis; Endocannabinoid system; Mood disorders

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; ENDOCANNABINOID; FATTY ACID AMIDASE; LIGAND; RIMONABANT; TETRAHYDROCANNABINOL;

ARTICLE; BIPOLAR DISORDER; DEPRESSION; HUMAN; HYPOMANIA; HYPOTHESIS; IMMUNE SYSTEM; MANIA; MOOD DISORDER; NERVE ENDING; NEUROBIOLOGY; NEUROMODULATION; PATHOPHYSIOLOGY; PUBLICATION;

EID: 79955050832     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association 2000.
2. Koukopoulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-67. (Pubitemid 10048336)
3. Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord 2003;73:75-85. (Pubitemid 36044635)
4. Baldessarini RJ. Drugs and the Treatment of Psychiatric Disorders: Depression and Anxiety Disorders. In: Griffith Hardman J, Limbird LE, Gilman AG, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Tenth edition. New York: McGraw-Hill 2001, pp. 447-520.
5. Serra G. The use of memantine as antimanic and mood stabilizer for the treatment of bipolar mood disorders resistant to conventional treatment. European Patent Bullettin, 33, 18-08-2010.
6. Koukopoulos A, Reginaldi D, Serra G, et al. Antimanic and mood stabilizing effect of memantine as augmenting agent in treatment resistant bipolar disorder. Bipolar Disord 2010;12:348-9.
7. Devane WA, Dysarz FA, Johnson M, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613. (Pubitemid 19007296)
8. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology XXVII Classification of Cannabinoid Receptors. Pharmacol Rev 2002;54:161-202.
9. Herkenham M, Lynnm AB, Johnson R, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;33:263-583.
10. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-84. (Pubitemid 37351427)
11. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors:immunohistochemical localization in rat brain. Brain Res. 2006;1071:10-23. (Pubitemid 43255471)
12. Onaivi ES, lshiguro H, Sejal P, et al. Methods to study the behavioural effects and expression of CB2 cannabinoid receptor and its gene transcripts in the in the chronic mild stress model of depression. Methods MoI Med 2006;123:291-8.
13. Devane WA, Dysarz FA, Johnson M, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13. (Pubitemid 19007296)
14. Howlett AC, Bidaut-Russel M, Devane WA, et al. The cannabinoid receptor: biochemical, anatomical and behavioural characterization. Trends Neurosci 1990;13:420-3. (Pubitemid 20297469)
15. Demuth DG, Molleman A. Cannabinoid signalling. Life Sci 2006;78:549-63. (Pubitemid 41785760)
16. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science 1992;258:1946-9. (Pubitemid 23026736)
17. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2Monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
18. Sugiura T, Kondo S, Sukagawa A, et al. 2Arachidonoylglycerol, a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
19. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-8. (Pubitemid 27375156)
20. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-7. (Pubitemid 26374593)
21. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002;99:10819-24.
22. Rodriguez De Fonseca F, Del Arco I, Bermudez-Silva FJ, et al. The endocannabinoid system:physiology and pharmacology. Alcohol Alcohol 2005;40:2-14.
23. Fattore L, Deiana S, Spano SM, et al. Endocannabinoid system and opioid addiction:behavioural aspects. Pharmacol Biochem Behav 2005;81:343-59. (Pubitemid 40807132)
24. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81:331-42. (Pubitemid 40807131)
25. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-22.
26. th edition. New York: McGraw-Hill 2006, pp. 429-59.
27. Delgado Pl. Depression: The case for a monoamine deficiency. J Clin Psychiatry 2000;61 (Suppl 6):7-11.
28. Heninger GR, Delgado Pl, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996;29:2-11. (Pubitemid 26071332)
29. Garver DL, Davis JM. Biogenic amine hypothesis of affective disorders. Life Sci 1979;24:383-94. (Pubitemid 9130129)
30. Sugrue MF. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 1983;21:1-33. (Pubitemid 13042192)
31. D'Aquila PS, CoIIu M, Gessa GL, et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Phamacol 2000;405:365-73.
32. Nestler EJ, Carlezon W. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9. (Pubitemid 44192421)
33. Macqueen GM, Campbell S, Mcewen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 2003;100:1387-92.
34. Videbech P, Ravnkilde B. Hippocampal volume and depression. A meta-analysis of MRI studies. Am J Psychiatry 2004;161:1957-66. (Pubitemid 39441394)
35. Sheline YI, Gado Mokhtar H, Kroemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-8.
36. Malberg JE. Implication of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci 2004;29:196-205.
37. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;8:301:805-9.
38. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006;16:239-49.
39. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 2005;11:1495-510.
40. D'sa C, Eisch AJ, Bolger GB, et al. Differential expression and regulation of the cAMP selective phosphodiesterase type 4a splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci 2005;22:1463-75.
41. Blendy JA. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006;59:1144-50.
42. Duman RS, Heninger GR, Nestler J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
43. Young T, Bakish D, Beaulieu S. The neurobiology of treatment response to antidepressants and mood stabilizing medications. J Psychiatry Neurosci 2002;27:260-5.
44. Holboer F. The corticosteroid hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
45. Tichomirova MA, Keck ME, Schneider HJ, et al. Endocrine disturbances in depression. J Endocrinol Invest 2005;28:89-99.
46. Sapolsky RM. Glucocorticioids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
47. Wong EY, Hrrbert J. Raised circulating corticosterone inhibits neuronal differentiation of progenitor cells in the adult hippocampus. Neuroscience 2006;137:83-92.
48. Ridder S, Chourbaji S, Hellweg R, et al. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 2005;25:6243-50.
49. Berk M, Dodd S, Kauer-Sant'anna M, et al.: Dopamine dysregulation syndrome: implications for a dopamine hypotesis of bipolar disorders. Acta Psychiatr Scand 2007;434(Suppl):41-9.
50. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009;11:787-806.
51. Martin M, Ledent C, Parmentier M, et al. Involvement of CB1 cannabinoid receptors In emotional behaviour. Psychopharmacology 2002;159:379-87.
52. Carai MA, Colombo G, Maccioni P, et al. Efficacy of Rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006;12:91-9.
53. Hill MN, Carrier EJ, McLaughlin RJ, et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008;106:2322-36.
54. Rodriguez-Gaztelumendi A, Rojo ML, Pazos A, et al. Altered CB1 receptor-signaling in prefrontal cortex from an animal model of depression reversed by chronic fluoxetine. J Neurochem 2009;108:1423-33.
55. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005;15:593-9.
56. Shearman LP, Rosko KM, Fleischer R, et al. Antidepressant-like and anorexic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003;14:573-82.
57. Tzavara ET, Davis RJ, Perry RW, et al. The CB1 receptor antagonist SR141716 selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. BrJ Pharmacol 2003;138:544-53.
58. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinod CB1 receptor antagonist Rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005;57:261-7.
59. Jin K, Xie L, Kim SH, et al. Defective adult neurogenesis in CB1 cannabinoid receptor Knockout mice. Mol Pharmacol 2004;66:204-8.
60. Bogliolo V, Garzia A, Serra G, et al. Effetto antidepressivosimile del rimonabant nel FST: un falso positivo. XVII Congresso Nazionale SINF Cagliari 22-25 Sett. 2010.
61. Garzia A, Bogliolo V, Loi F, et al. L'agonista del recettore CB1, HU-210, ma non l'antagonista rimonabant, antagoniza la sindrome reserpinica nel ratto. XVII Congresso Nazionale SINF Cagliari 22-25 Sett. 2010.
62. Food and Drug Administration (FDA)'s Endocrinologic and Metabolic Drugs Advisory Committee: June 13, 2007.
63. European Medicines Agency (EMEA)'s Committee for Medicinal Products for Human use (CHMP): July 19, 2007.
64. EMEA: Suspended.
65. McLaughlin Rj, Hill MN, Morrish AC, et al. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav Pharmacol 2007;18:431-8.
66. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005;15:593-9.
67. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102:18620-5.
68. Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007;62:1103-10.
69. Naidu PS, Varvel SA, Ahn K, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 2007;192:65-70.
70. Rutkowska M, Jachimezuk O. Antidepressant-like properties of ACEA(Arachidonyl-2-Chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 2004;61:165-7.
71. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects. J Clin Invest 2005;115:3104-16.
72. Bambico FR, Duranti A, Tontini A, et al. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 2009;15:1623-46.
73. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group: effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
74. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006;47:1919-26.
75. Ashton CH, Moore P, Gallangher P, et al. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol 2005;19:293-300.
76. Gruber AJ, Pope HG, Brown ME. Do patients use marijuana as man antidepressant? Depression 1996;4:77-80.
77. Grinspoon L, Balkar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998;30:171-7.
78. Henquet C, Krabbendam L, Degraaf R, et al. Cannabis use and expression of mania in the general population. J Affect Disord 2006;95:103-10.
79. Nunez Dominguez LA. Cannabis use and bipolar disorder. Bipolar Disord 2006;5:60-62.
80. Johns A. The psychiatric effects of cannabis. Br J Psychiatry 2001;178:116-22.
81. Cassidy F, Ahearn EP, Carrol BJ. Substance abuse in bipolar disorders. Bipolar Disord 2001;3:181-8.
82. Dalton EJ, Cate-Carter TD, Mundo E, et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003;3:58-61.
83. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008;13:264-75.
84. Moreau de Tours J. Du Hashish et de la alienation mentale. Etudes Psychologiques. Paris: Librairie de Fortin, Masson 1845.
85. Thomas HA. Community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996 ;42:201-7.
86. Tohen M, Vieta E, Gonzalez-Pinto A, et al., for the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Advisory Board. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry 2010;71:255-61.
87. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558-72.
88. Favrat B, Ménétrey A, Augsburger M, et al. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry 2005;5:17.
89. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008;33:2505-16.
90. Goodwin FK, Jaminson K. Manic-Depressive Illness. New York: Oxford University Press 2009.
91. Hungund BL, Vinod KY, Kassir SA, et al. Up-regulation of CB1 receptors and agonist-stimulated (35s)GTPgs binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004;9:184-90.
92. Vinod KI, Arango V, Xie S, et al. Elevated levels of endocannabinoids and CB1 receptormediated G-protein signalling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 2005;57:480-6.
93. Denson TF, Earleywine M. Decreased depression in marijuana users. Addict Behav 2006;31;738-42.
94. Gruber AJ, Pope HG Jr, Brown ME. Do patients use marijuana as an antidepressant? Depression 1996;4;77-80.
95. Hill MN, Hillard CJ, Bambico FR, et al. The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants. Trends Pharmacol Sci 2009;30:484-93.
96. Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11;563-83.
97. Hill MN, Miller GE, Carrier EJ, et al. Dynamic regulation of serum endocannabinoid content in affective disease and following social stress in humans. (Abstract) 16th Annual Symposium On The Endocannabinoids Tihany, Hungary June 24-28, 2006.
98. Miller GE, Hill MN, Ho WS, et al. Bidirectional alterations in serum endocannabinoids in minor and major depression. Program No 107.3 (Abstract) Viewer/Itinerary Planner. Washington, DC: Society For Neuroscience 2005.
99. Koethe D, Lienos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007;114:1055-68.
100. Domschke K, Dannlowski U, Ohrmann P, et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008;18:751-9.
101. Derkinderen P, Valjent E, Toutant M, et al. Regulation of extracellular signalregulated kinase by cannabinoids in hippocampus. J Neurosci 2003;23:2371-82.
102. Jiang, W. et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005;115;3104-16.
103. Aso E, Ozaita A, Valdizán EM, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008;105:565-72.
104. Aguado T, Monory K, Palazuelos J, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005;19:1704-6.
105. Jin K, Xie L, Kim SH, et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 2004;66:204-8.
106. Hill MN, Titterness AK, Morrish AC, et al. Endogenous Cannabinoid Signaling Is Required for Voluntary Exercise-induced Enhancement of Progenitor Cell Proliferation in the Hippocampus. Hippocampus 2010;20:513-23.